Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentra cerrado desde el 19 de junio. La solicitud de ayudas para los Bonos 1, 2 y 4 permanecen abiertos.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
245
resultados
Última actualización
14/08/2025 [06:52:00]
Resultados 50 a 75 de 245
Resumen de: CN120437080A
本发明提供了一种吸入式有机纳米颗粒疫苗及其制备方法和应用。所述吸入式有机纳米颗粒疫苗包括有机高分子聚合物、免疫佐剂、抗原，所述有机纳米颗粒疫苗形貌良好，颗粒均一、制备简单，具有安全性好、免疫方案便捷、保护率高等特性，对预防病原体感染具有显著效果。所述有机高分子聚合物表面带有正电荷，有利于通过静电吸附作用负载免疫佐剂，其具有的环状氨基拥有质子海绵效应，可介导免疫佐剂溶酶体逃逸，既能高效负载抗原和佐剂，也能实现抗原和佐剂的靶向共递送。
Resumen de: WO2025166202A1
The present disclosure provides lipids comprising a sialic acid moiety (sialic acid lipids) and lipid nanoparticles suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs) and myleloid and lymphoid cells, wherein the lipid nanoparticles comprise a sialic acid lipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid nanoparticles. The sialic acid lipids have formula (SA-1).
Resumen de: AU2023320333A1
Provided herein are immunomodulatory proteins and compositions (
Resumen de: WO2025163179A1
The present invention refers to a composition comprising BMNPs (Biomimetic magnetic nanoparticles) or BMNP nanoassemblies, characterized in that said BMNPs are disaggregated or dispersed. Alternatively, the first aspect of the present invention refers to a composition comprising: (i) a substantially pure mineral phase of superparamagnetic magnetite, (ii) the MamC protein, and (iii) optionally, the Mms6 and/or Mms7 protein; wherein, at least components (i) and (ii) form superparamagnetic magnetic nanoparticles containing up to 20 wt% of MamC, with a mean particle size between 30 and 120 nm, preferably between 30 and 50 nm, more preferably about 39±7 nm, characterized in that said superparamagnetic magnetic nanoparticles containing MamC are disaggregated or dispersed.
Resumen de: WO2025165999A1
Disclosed are compositions, methods, and kits related to lipid nanoparticles (LNPs) comprising ionizable lipids. The LNPs can comprise mRNA encoding therapeutic peptides for immunotherapy. The LNPs can preferentially deliver a therapeutic payload to a target organ.
Resumen de: WO2025165798A1
The present invention provides a pharmaceutical composition comprising one or more RNA polymerase primary σ70 (encoded by gene rpoD) targeting polynucleotides capable of targeting rpoD. In an embodiment, the one or more rpoD targeting polynucleotides is encapsulated in a nanoparticle such as exosomes or LNP. The present invention also provides a method of treatment of rpoD-associated disease of a subject comprising administration of a therapeutically effective amount of the pharmaceutical composition of the present invention to the subject.
Resumen de: WO2025165896A1
Provided herein is a bottlebrush polyethylene glycol (PEG-BB) nanocarrier that can translocate across all barriers within the human airway surface.
Resumen de: WO2025166373A1
Engineered nanoparticles for genetic therapies in human blood cells are described and can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases. Targeting of human stem cells is achieved through the binding of CD133, CD117, CD90, with linked targeting moieties that result in rapid internalization of the engineered nanoparticles following binding.
Resumen de: WO2025165991A1
A process and system for removal of antibiotic compounds from a patient's body can include having a patient digest an antibiotic removal agent or an antibiotic deactivation agent. The agent can include anionic hairy cellulose nanocrystals (AHCNC) hybridized with a resin, such as cholestyramine (CHA). The agent can pass through the patient's digestive system to remove antibiotic compounds that may reside therein as a consequence of an antibacterial treatment provided to the patient. Removal of the antibiotic compounds from the patient's digestive system can avoid evolution of antimicrobial resistance.
Resumen de: WO2025165797A1
The present invention comprises a pharmaceutic composition comprising one or more hepatocyte nuclear factor four alpha antisense RNA 1 (HNF4A-AS1) targeting polynucleotides, wherein the one or more HNF4A-AS1 targeting polynucleotides is capable of repressing HNF4A-AS1 in a subject resulting in upregulation of HNF4A expression and/or increasing HNF4A P1:P2 isoform ratio in the subject. The present invention also provides a method of treatment of a HNF4A-associated disease in a subject comprising the step of administering a therapeutically effective amount of the pharmaceutical composition comprising one or more HNF4A- AS1 targeting polynucleotides of the present invention. The present invention also provides a method of downregulating HNF4A P2 isoform expression in a subject comprising the step of repressing HNF4A-AS1 in the subject.
Resumen de: WO2025164564A1
The present invention provides a production method that makes it possible to obtain nucleic acid-encapsulating lipid nanoparticles having improved particle size distribution uniformity and improved gene expression efficiency. A nucleic acid-encapsulating lipid nanoparticle production method according to the present invention comprises mixing a lipid solution containing a PEG-lipid, an ionizable lipid, a phospholipid, a structural lipid, and a solvent with an aqueous nucleic acid solution, wherein at least part of the solvent in the lipid solution is pyridine.
Resumen de: WO2025165163A1
The present invention relates to an albumin nanoplatform for boron neutron capture therapy and a composition for boron neutron capture therapy comprising same. The albumin-based nanoplatform according to the present disclosure can effectively deliver boron to specific tumor tissues by simultaneously conjugating a boron compound containing an excessive amount of boron and a targeting molecule as a carrier for specifically targeting tumor tissues via click chemistry functional groups introduced into the albumin surface. In particular, the nanoplatform enables sufficient delivery of boron molecules to target tumor tissues even at doses less than one-tenth of those required by conventional boron neutron capture therapy (BNCT) drugs, and thus can be applied as a composition for boron neutron capture therapy and as an anticancer therapeutic agent.
Resumen de: WO2025164841A1
The present invention can provide a composition for treating gout or a method for treating gout, the composition containing a nano-drug in which a cyclodextrin moiety is conjugated to an amino group of a polymer, wherein a visible or near-infrared fluorophore is further conjugated to a carboxyl group of the polymer or the nano-drug further contains at least one gout therapeutic agent, which forms a complex together with the cyclodextrin moiety.
Resumen de: WO2025164815A1
The present invention relates to a novel peptide having binding affinity to ACE2 and uses thereof and, more specifically, to: a peptide represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4, and having binding affinity to ACE2; a nanocarrier and a drug complex, each comprising the peptide; and a pharmaceutical composition for preventing or treating COVID-19, comprising the peptide, the nanocarrier, or the drug complex. The novel peptide according to the present invention can be used to increase the COVID-19 therapeutic effect through specific binding to ACE2-expressing cells.
Resumen de: WO2025163677A1
The present disclosure relates to a micellar composition, an active/passenger molecule/ plant, animal or marine extract loaded micellar composition, process for the preparation of micellar composition and active/passenger molecule/ plant, animal or marine extract loaded micellar composition. Remarkably, the process is simple, optionally employing any organic solvent. The micellar composition is invariably transparent and shows high permeation and an extended-release drug delivery system.
Resumen de: WO2025163665A1
The present invention relates to a stable pharmaceutical composition of abiraterone or pharmaceutically acceptable salt thereof. Specifically, it relates to a stable pharmaceutical composition comprising a nanosuspension of abiraterone or pharmaceutically acceptable salt thereof that reduces the dose, lessen the pill burden, enhance the bioavailability of abiraterone in fasting conditions and reduce the food effect as compared to commercial products. A method of preparation of the said composition is also disclosed. Additionally, the invention pertains to the methods of treating certain cancers in mammalian subjects using the said composition.
Resumen de: WO2025162298A1
A nano eye drop capable of delivering a drug to the posterior eye segment, and a preparation method therefor and the use thereof. The nano eye drop comprises a liposome core and a chitosan shell, wherein the liposome core can load a hydrophilic and/or hydrophobic drug, and prolong the retention time of the drug on the ocular surface and enhance the ocular permeability of the drug.
Resumen de: WO2025161943A1
Disclosed in the present application are a compound having a structural formula as shown in formula (I), and a pharmaceutically acceptable salt thereof or a stereoisomer thereof. Further disclosed in the present application is a nanoparticle composition containing the compound or the pharmaceutically acceptable salt thereof or the stereoisomer thereof. The nanoparticle of the present application can efficiently deliver a drug and a vaccine into a cell, thereby exerting the therapeutic or prophylactic purpose of the drug and the vaccine.
Resumen de: WO2025162105A1
The invention provides a HPV mRNA lipid nanoparticle vaccine, comprising an open reading frame encoding a fusion protein of E2, E6 and E7 antigens of a high-risk HPV antigen. The invention also provides a method for treating and preventing HPV infection related diseases such as cervical cancer, cervical precancerous lesions, high-grade intraepithelial lesions of the cervix, high-grade squamous intraepithelial lesions (HSIL) or cervical intraepithelial neoplasia (CIN).
Resumen de: AU2024245504A1
The present invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal according to which: - a first composition/solution 1 containing an aluminum source and a source of an ion of an alkali metal M, in particular Na, is prepared; a second composition/solution 2 comprising a silicon source and a source of an ion of an alkali metal M, in particular Na, is prepared, said solutions 1 and 2 being free of any organic structuring agent; - the two compositions/solutions 1 and 2 are mixed; - the mixture is crystallized; and - said nanoparticles thus formed are optionally separated. According to the invention, said first composition/solution 1 and said second composition/solution 2 are both constituted of said source and of an alkaline phosphate buffer (PBS). The present invention also relates to the nanoparticles obtained and compositions containing them.
Resumen de: AU2024212425A1
Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, glucosyl cholesterol; and modified by (b) an ionizable lipid. The disclosure also includes a method for making a modified lipid composition, comprising reconstructing (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, and/or glucosyl cholesterol in the presence of (b) an ionizable lipid, to produce the modified lipid composition, and loading into the modified lipid composition with one or more heterologous functional agents.
Resumen de: AU2023408533A1
The present invention relates to a process of preparing stable nanoparticles and pharmaceutical composition thereof. Moreover, the nanoparticles prepared from the process are with a stable and controlled mean particle size and particle size distribution.
Resumen de: AU2023408649A1
The present invention provides, in part, bis-ester and amide cationic lipid compounds of Formula (I):, or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (II):, or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (III):, or a pharmaceutically acceptable salt thereof, and bis-ester and amide cationic lipid compounds of Formula (IV):, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Resumen de: WO2025161942A1
The present application discloses a compound having a structural formula as shown in formula (I), and a pharmaceutically acceptable salt or stereoisomer thereof. The present application further discloses a nanoparticle composition containing the compound or the pharmaceutically acceptable salt or stereoisomer thereof. The nanoparticles of the present application can efficiently deliver drugs and vaccines into cells, thereby achieving the treatment or prevention effects of drugs and vaccines.
Nº publicación: JP2025116093A 07/08/2025
Solicitante:
オーハイエナジェティクスピービーシー
Resumen de: EP4556457A2
The present disclosure relates to cannabinoid compositions used in combination with stem cell therapies. These compositions can be encapsulated (e.g., microencapsulated). In particular, these compositions can be administered to a subject, such as through oral consumption or topical treatment.
BOPI
Sede Electrónica
